GenSight Biologics S.A. (FRA:G49N)

Market Cap	19.15M
Revenue (ttm)	945.00K
Net Income (ttm)	-15.12M
Shares Out	n/a
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	219
Open	0.0960
Previous Close	0.0934
Day's Range	0.0960 - 0.0960
52-Week Range	0.0934 - 0.3285
Beta	n/a
RSI	41.81
Earnings Date	Mar 24, 2026

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 16
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: G49N

Financial Performance

In 2024, GenSight Biologics's revenue was 2.63 million, a decrease of -11.44% compared to the previous year's 2.96 million. Losses were -14.00 million, -46.60% less than in 2023.